Skip to main content

Table 4 Severe (grade 3–5) acute toxicity during concurrent chemoradiation and adjuvant chemotherapy

From: A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events

 

SEQ

SIB

p-value

Severe acute toxicity during concurrent chemoradiation

 

 Weight loss

5.9 %

6.2 %

1.000*

 Oral mucositis

15.4 %

13.6 %

0.788

 Dysphagia

9.6 %

9.1 %

1.000*

 Xerostomia

9.6 %

7.6 %

0.748*

 Dermatitis

7.7 %

9.1 %

1.000*

Severe acute toxicity during adjuvant chemotherapy

 

 Weight loss

20 %

27.3 %

0.459

 Dysphagia

2 %

1.5 %

1.000*

  1. *Fischer’s exact test was used due to low expected count data